These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 9511060)

  • 1. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
    Kang SL; Rybak MJ
    J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.
    Williams JD; Maskell JP; Whiley AC; Sefton AM
    J Antimicrob Chemother; 1997 May; 39 Suppl A():41-6. PubMed ID: 9511061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium.
    Hill RL; Smith CT; Seyed-Akhavani M; Casewell MW
    J Antimicrob Chemother; 1997 May; 39 Suppl A():23-8. PubMed ID: 9511058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro activities of quinupristin/dalfopristin in combination with vancomycin and gatifloxacin against Staphylococcus aureus and Enterococcus faecium clinical isolates].
    Gülden E; Ermertcan S
    Mikrobiyol Bul; 2009 Jan; 43(1):53-60. PubMed ID: 19334380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium.
    Lorian V; Fernandes F
    J Antimicrob Chemother; 1997 May; 39 Suppl A():63-6. PubMed ID: 9511065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.
    Allen GP; Cha R; Rybak MJ
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2606-12. PubMed ID: 12121940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci.
    Eliopoulos GM; Wennersten CB
    Antimicrob Agents Chemother; 2002 May; 46(5):1319-24. PubMed ID: 11959562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium.
    Bonilla HF; Perri MB; Kauffman CA; Zervos MJ
    Diagn Microbiol Infect Dis; 1996 Jul; 25(3):127-31. PubMed ID: 8902408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of vancomycin and other antimicrobial agents against methicillin-resistant staphylococcus aureus and enterococcus faecium in the Tohoku district of Japan.
    Lutfor AB; Kikuchi T; Tokue Y; Takahashi H; Shoji S; Fujimura S; Nukiwa T; Watanabe A
    Chemotherapy; 1998; 44(5):318-23. PubMed ID: 9732146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of quinupristin/dalfopristin alone or in combination with vancomycin on the structure of Enterococcus faecium.
    Lorian V; Fernandes F
    Drugs Exp Clin Res; 1998; 24(2):73-6. PubMed ID: 9675547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
    Rybak MJ; Hershberger E; Moldovan T; Grucz RG
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus.
    Low DE; Nadler HL
    J Antimicrob Chemother; 1997 May; 39 Suppl A():53-8. PubMed ID: 9511063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
    Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
    Sambatakou H; Giamarellos-Bourboulis EJ; Grecka P; Chryssouli Z; Giamarellou H
    J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.
    Matsumura SO; Louie L; Louie M; Simor AE
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2776-9. PubMed ID: 10543762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
    Drago L; Nicola L; De Vecchi E
    Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium.
    Winston DJ; Emmanouilides C; Kroeber A; Hindler J; Bruckner DA; Territo MC; Busuttil RW
    Clin Infect Dis; 2000 May; 30(5):790-7. PubMed ID: 10817685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations.
    Aeschlimann JR; Zervos MJ; Rybak MJ
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2710-7. PubMed ID: 9756782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
    Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.